Targeting p35/Cdk5 signalling via CIP-peptide promotes angiogenesis in hypoxia

PLoS One. 2013 Sep 30;8(9):e75538. doi: 10.1371/journal.pone.0075538. eCollection 2013.

Abstract

Cyclin-dependent kinase-5 (Cdk5) is over-expressed in both neurons and microvessels in hypoxic regions of stroke tissue and has a significant pathological role following hyper-phosphorylation leading to calpain-induced cell death. Here, we have identified a critical role of Cdk5 in cytoskeleton/focal dynamics, wherein its activator, p35, redistributes along actin microfilaments of spreading cells co-localising with p(Tyr15)Cdk5, talin/integrin beta-1 at the lamellipodia in polarising cells. Cdk5 inhibition (roscovitine) resulted in actin-cytoskeleton disorganisation, prevention of protein co-localization and inhibition of movement. Cells expressing Cdk5 (D144N) kinase mutant, were unable to spread, migrate and form tube-like structures or sprouts, while Cdk5 wild-type over-expression showed enhanced motility and angiogenesis in vitro, which was maintained during hypoxia. Gene microarray studies demonstrated myocyte enhancer factor (MEF2C) as a substrate for Cdk5-mediated angiogenesis in vitro. MEF2C showed nuclear co-immunoprecipitation with Cdk5 and almost complete inhibition of differentiation and sprout formation following siRNA knock-down. In hypoxia, insertion of Cdk5/p25-inhibitory peptide (CIP) vector preserved and enhanced in vitro angiogenesis. These results demonstrate the existence of critical and complementary signalling pathways through Cdk5 and p35, and through which coordination is a required factor for successful angiogenesis in sustained hypoxic condition.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Actin Cytoskeleton / metabolism
  • Adaptor Proteins, Signal Transducing / metabolism*
  • Analysis of Variance
  • Blotting, Western
  • Cell Cycle Proteins / metabolism*
  • Cell Line
  • Cell Movement / drug effects
  • Colorimetry
  • Cyclin-Dependent Kinase 5 / antagonists & inhibitors
  • Cyclin-Dependent Kinase 5 / genetics
  • Cyclin-Dependent Kinase 5 / metabolism*
  • Cytoskeleton / drug effects
  • DNA Primers / genetics
  • Humans
  • Hypoxia / drug therapy*
  • Hypoxia / etiology
  • Hypoxia / metabolism
  • Immunoprecipitation
  • MEF2 Transcription Factors / metabolism
  • Microarray Analysis
  • Microscopy, Fluorescence
  • Mutation, Missense / genetics
  • Neovascularization, Physiologic / drug effects
  • Neovascularization, Physiologic / physiology*
  • Peptides / metabolism
  • Peptides / pharmacology
  • Pseudopodia / metabolism
  • Purines / pharmacology
  • RNA Interference
  • Roscovitine
  • Signal Transduction / drug effects
  • Signal Transduction / physiology*
  • Stroke / complications*

Substances

  • Adaptor Proteins, Signal Transducing
  • CDCA5 protein, human
  • Cell Cycle Proteins
  • DNA Primers
  • MEF2 Transcription Factors
  • MEF2C protein, human
  • Peptides
  • Purines
  • Roscovitine
  • Cyclin-Dependent Kinase 5
  • CDK5 protein, human